Amsterdam University Medical Center Reports Findings in Hypercholesterolemia (Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial).
In: Pediatrics Week, 2024-02-19, S. 59-59
serialPeriodical
Zugriff:
A recent study conducted at Amsterdam University Medical Center evaluated the efficacy of alirocumab, a lipid-lowering therapy, in pediatric patients with heterozygous familial hypercholesterolemia (HeFH). The study included 153 patients aged 8 to 17 years who were already receiving statins or other lipid-lowering therapies. The results showed that alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in both dosing cohorts (every 2 weeks or every 4 weeks) compared to placebo. The study concluded that alirocumab may be a useful adjunct therapy for pediatric patients with HeFH who have inadequate control with statins. [Extracted from the article]
Copyright of Pediatrics Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Amsterdam University Medical Center Reports Findings in Hypercholesterolemia (Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial).
|
---|---|
Zeitschrift: | Pediatrics Week, 2024-02-19, S. 59-59 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1944-2637 (print) |
Schlagwort: |
|
Sonstiges: |
|